

Title:

Large cell neuroendocrine carcinoma at the esophagogastric junction. An extremely rare entity

Authors:

Manuel García-Redondo, José Ruiz Pardo, Pedro Antonio Sánchez Fuentes, Elisabet Vidaña Márquez, Ricardo Belda Lozano, Álvaro Pérez-Rodríguez, Íñigo Gorostiaga, Ángel Reina Duarte

DOI: 10.17235/reed.2023.9505/2023 Link: <u>PubMed (Epub ahead of print)</u>

Please cite this article as:

García-Redondo Manuel, Ruiz Pardo José, Sánchez Fuentes Pedro Antonio, Vidaña Márquez Elisabet, Belda Lozano Ricardo, Pérez-Rodríguez Álvaro, Gorostiaga Íñigo, Reina Duarte Ángel. Large cell neuroendocrine carcinoma at the esophagogastric junction. An extremely rare entity. Rev Esp Enferm Dig 2023. doi: 10.17235/reed.2023.9505/2023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Revista Española de Enfermedades Digestivas The Spanish Journal

CC 9505 inglés

Large cell neuroendocrine carcinoma at the esophagogastric junction. An extremely

rare entity

Manuel García-Redondo¹, José Ruiz Pardo¹, Pedro Sánchez-Fuentes¹, Elisabet Vidaña

Márquez¹, Ricardo Belda Lozano¹, Álvaro Pérez-Rodríguez², Íñigo Gorostiaga², Ángel

José Reina Duarte¹

Departments of ¹General and Digestive Surgery and ²Pathology. Hospital Universitario

Torrecárdenas. Almería, Spain

Correspondence: Manuel García-Redondo

e-mail: m.garcia.redondo@outlook.es

Conflict of interest: the authors declare no conflict of interest.

Keywords: Neuroendocrine carcinoma. Large cell. Esophagogastric junction. Large cell

neuroendocrine carcinoma.

Dear Editor,

neuroendocrine 0.04-1 % of Esophageal tumors (NETs) account for all

gastroenteropancreatic NETs and 0.03-0.05 % of all malignant esophageal tumors.

Within esophageal NETs, small cell neuroendocrine carcinoma accounts for more than

90 % of cases, with well-differentiated NETs, large cell neuroendocrine carcinoma

(LCNEC) and mixed neuroendocrine neoplasms being much less frequent (1).

Specifically, LCNEC accounts for 1 % of esophageal NETs (2). Due to the infrequency of

this condition, we describe the case of a patient with an LCNEC at the level of the

esophagogastric junction (EGJ).

Case report



A 65-year-old male, ex-smoker with chronic obstructive pulmonary disease, consulted due to epigastric pain of two months duration, associated with constitutional syndrome. An upper gastrointestinal endoscopy was performed and a friable, ulcerated tumor was identified at the level of the esophagogastric junction, and a biopsy was taken. As the biopsy was compatible with LCNEC of the EGJ (Siewert II), the study was completed with echoendoscopy and computed tomography, without finding locoregional adenopathies or distant metastases (cT2NOMO). Total gastrectomy with distal esophagectomy and associated lymphadenectomy was performed. Finally, histopathological analysis revealed a 2.5 cm LCNEC with involvement down to the submucosa, with positive expression of CDX2, CD56 and synaptophysin, Ki67 of 70 % and associated intestinal metaplasia in the distal esophagus. The resection margins were free of disease and there was no evidence of metastatic adenopathy in the 16 isolated nodes (pT1bN0MO). After six months of follow-up, the patient is asymptomatic and free of disease.

Discussion

LCNEC of the intestinal tract occurs in the EGJ in 9.7 % of cases (3). Thus, five cases of LCNEC of the EGJ have been documented in the scientific literature, two described (2,4) (Table 1) and three reported in a retrospective study (3).

LCNEC from the intestinal tract is positive for chromogranin A in 71 %, synaptophysin in 94 % and CD56 in 54 %. However, 100 % of patients will have chromogranin or synaptophysin, or at least one of these three markers. In turn, 78 % will have lymphovascular invasion and 26 % perineural invasion (3). Only 11 % of patients will have stage I-II (3), which implies an aggressive course and worse prognosis (2-4). Finally, it should be noted that distal esophageal and EGJ NETs can be associated with intestinal metaplasia (Barrett's esophagus) (2,5).

References

1. Mastracci L, Rindi G, Grillo F, et al. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica 2021;113:5-11. DOI: 10.32074/1591-951X-229



- 2. Ichimata S, Aoyagi D, Takehana T, et al. A case of large cell neuroendocrine carcinoma exhibiting rhabdoid features in the esophagogastric junction: a case of neuroendocrine carcinoma exhibiting rhabdoid. Pathol Int 2019;69:481-7. DOI: 10.1111/pin.12807
- 3. Shia J, Tang LH, Weiser MR, et al. Is non-small cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008;32:719-31. DOI: 10.1097/PAS.0b013e318159371c
- 4. Fukuchi M, Sakurai S, Tsukagoshi R, et al. A case of large cell neuroendocrine carcinoma of the esophagogastric junction. Esophagus 2015;12:295-9. DOI: 10.1007/s10388-014-0443-7
- 5. Belvis Jiménez M, Guerra Veloz MF, Rodríguez-Téllez M. An esophageal neuroendocrine tumor in a Barrett's esophagus successfully treated with endoscopic resection. Rev Esp Enferm Dig 2020;112:885-6. DOI: 10.17235/reed.2020.6907/2020



Table 1. Cases of large cell neuroendocrine carcinoma of the esophagogastric junction described in the scientific literature

| | Fukuchi M et al. | Ichimata S et al. | García-Redondo M et al. |
|------------------------------|--|-------------------------|---|
| | (2015) (4) | (2019) (2) | (2023) |
| Age (years) | 65 | 81 | 65 |
| Sex | Male | Male | Male |
| Clinic | Heartburn for 5 months | Constitutional syndrome | Epigastric pain and constitutional syndrome for 2 months |
| Macroscopic appearance | Ulcerated tumor | Ulcerated tumor | Ulcerated tumor |
| Surgery | Distal esophagectomy, total gastrectomy, and lymphadenectomy (levels 1-11, 19, 20, 110, and 111) | Subtotal esophagectomy | Distal esophagectomy, total gastrectomy and lymphadenectomy (levels 1-9, 11, 12, 19, 20, 110 and 111) |
| Approach | Open | Thoracoscopy | Laparoscopic |
| Size (maximum diameter) (cm) | 5.5 | 4 | 2.5 |
| Invasion | Subserosa | Submucosa | Submucosa |
| Metastatic adenopathy | 6 of 30 isolated | Yes | 0 of 16 isolated |
| Synaptophysin | + | + | + |
| Chromogranin A | + | - | - |
| CD56 | + | - | + |
| Intestinal metaplasia | No | Yes | Yes |
| TNM | T3N2M0 | T1bN1M0 | T1bN0M0 |
| Adyuvant | Chemotherapy | No | No |



| Follow-up (months) | 9 | 18 | 6 |
|-----------------------|------------------|----|----|
| Recidivism | Liver metastases | No | No |
| Mortality | Yes | No | No |






Fig. 1. A. Upper gastrointestinal endoscopy showing a tumor at the esophagogastric junction with an ulcerated surface. B. Histological section showing large cell neuroendocrine carcinoma (LCNEC) infiltration adjacent to the esophagogastric junction mucosa (x20 hematoxylin-eosin). C. Immunohistochemistry: diffuse positivity of tumor cells for CD56 (40x). D. Immunohistochemistry: heterogeneous positivity in tumor cells for synaptophysin (40x).